Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development

Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States, and China, has announced the establishment of a new wholly-owned subsidiary, Nona Biosciences. The new unit will provide R&D solutions to clients for next-generation antibodies and other biotherapeutic development, covering the entire spectrum from discovery to the IND stage.

Subsidiary Profile
Nona Biosciences will leverage Harbour BioMed’s two core mice platforms for antibody and bispecific antibody development. The first platform, Harbour Mice, is designed for the generation of fully human monoclonal antibodies in both classical two light and two heavy chain (H2L2) format and heavy chain only (HCAb) format. The second platform, HBICE, is an HCAb-based immune cell engager specifically tailored for the development of bispecific antibodies. These platforms will enable Nona Biosciences to offer comprehensive R&D services, supporting clients in advancing their biotherapeutic pipelines.

Future Implications
The establishment of Nona Biosciences marks a strategic move by Harbour BioMed to expand its presence in the biotherapeutics market. By leveraging its advanced antibody development platforms, the new subsidiary is poised to play a significant role in the discovery and development of next-generation biotherapeutics, addressing unmet medical needs and contributing to the advancement of global healthcare.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry